Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

Clin Cancer Res (2012) 18 (21): 6032–6039.

https://doi.org/10.1158/1078-0432.CCR-12-1841

Published: 06 November 2012

View articletitled, Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

Includes: Supplementary data

Journal Articles

Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma

John G. Kuhn, Susan M. Chang, Patrick Y. Wen, Timothy F. Cloughesy, Harry Greenberg, David Schiff, Charles Conrad, Karen L. Fink, H. Ian Robins, Minesh Mehta, Lisa DeAngelis, Jeffrey Raizer, Kenneth Hess, Kathleen R. Lamborn, Janet Dancey, Michael D. Prados, for the North American Brain Tumor Consortium and the National Cancer Institute

Clin Cancer Res (2007) 13 (24): 7401–7406.

https://doi.org/10.1158/1078-0432.CCR-07-0781

Published: 19 December 2007

View articletitled, Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma

Journal Articles

Expression of the Hypoxia Marker Carbonic Anhydrase 9 Is Associated with Anaplastic Phenotypes in Meningiomas

Heon Yoo, Gilson S. Baia, Justin S. Smith, Michael W. McDermott, Andrew W. Bollen, Scott R. VandenBerg, Kathleen R. Lamborn, Anita Lal

Clin Cancer Res (2007) 13 (1): 68–75.

https://doi.org/10.1158/1078-0432.CCR-06-1377

Published: 02 January 2007

View articletitled, Expression of the Hypoxia Marker Carbonic Anhydrase 9 Is Associated with Anaplastic Phenotypes in Meningiomas

Journal Articles

Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

Clin Cancer Res (2006) 12 (16): 4899–4907.

https://doi.org/10.1158/1078-0432.CCR-06-0773

Published: 16 August 2006

View articletitled, Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

Journal Articles

High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody

Carol M. Richman, Sally J. DeNardo, Robert T. O'Donnell, Aina Yuan, Sui Shen, Desiree S. Goldstein, Joseph M. Tuscano, Ted Wun, Helen K. Chew, Primo N. Lara, David L. Kukis, Arutselvan Natarajan, Claude F. Meares, Kathleen R. Lamborn, Gerald L. DeNardo

Clin Cancer Res (2005) 11 (16): 5920–5927.

https://doi.org/10.1158/1078-0432.CCR-05-0211

Published: 22 August 2005

View articletitled, High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody

Journal Articles

Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma

Anjan Misra, Malgorzata Pellarin, Janice Nigro, Ivan Smirnov, Dan Moore, Kathleen R. Lamborn, Daniel Pinkel, Donna G. Albertson, Burt G. Feuerstein

Clin Cancer Res (2005) 11 (8): 2907–2918.

https://doi.org/10.1158/1078-0432.CCR-04-0708

Published: 18 April 2005

View articletitled, Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma

Journal Articles

Preclinical Evaluation of Cathepsin-degradable Peptide Linkers for Radioimmunoconjugates

Gerald L. DeNardo, Sally J. DeNardo, James J. Peterson, Laird A. Miers, Kit S. Lam, Christine Hartmann-Siantar, Kathleen R. Lamborn

Clin Cancer Res (2003) 9 (10): 3865s–3872s.

Published: 01 September 2003

View articletitled, Preclinical Evaluation of Cathepsin-degradable Peptide Linkers for Radioimmunoconjugates

Journal Articles

Effect of Molecular Size of Pegylated Peptide on the Pharmacokinetics and Tumor Targeting in Lymphoma-Bearing Mice

Sally J. DeNardo, Zhengsheng Yao, Kit S. Lam, Aimin Song, Patricia A. Burke, Gary R. Mirick, Kathleen R. Lamborn, Robert T. O’Donnell, Gerald L. DeNardo

Clin Cancer Res (2003) 9 (10): 3854s–3864s.

Published: 01 September 2003

View articletitled, Effect of Molecular Size of Pegylated Peptide on the Pharmacokinetics and Tumor Targeting in Lymphoma-Bearing Mice

Journal Articles

Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane- N , N ′, N ″, N ‴-Tetraacetic Acid (DOTA)-Peptide versus 2IT-DOTA Monoclonal Antibody Linkage for RIT

Sally J. DeNardo, Gerald L. DeNardo, A. Yuan, Carol M. Richman, Robert T. O’Donnell, Primo N. Lara, David L. Kukis, Arutselvan Natarajan, Kathleen R. Lamborn, Frederik Jacobs, Christine L. Hartmann Siantar

Clin Cancer Res (2003) 9 (10): 3938s–3944s.

Published: 01 September 2003

View articletitled, Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane- N , N ′, N ″, N ‴-Tetraacetic Acid (DOTA)-Peptide versus 2IT-DOTA Monoclonal Antibody Linkage for RIT

Journal Articles

Characterization of Human IgG Antimouse Antibody in Patients with B-Cell Malignancies

Gerald L. DeNardo, Gary R. Mirick, Linda A. Kroger, Bonnie M. Bradt, Kathleen R. Lamborn, Sally J. DeNardo

Clin Cancer Res (2003) 9 (10): 4013s–4021s.

Published: 01 September 2003

View articletitled, Characterization of Human IgG Antimouse Antibody in Patients with B-Cell Malignancies

Journal Articles

Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy

Michelle D. Winthrop, Sally J. DeNardo, Huguette Albrecht, Gary R. Mirick, Linda A. Kroger, Kathleen R. Lamborn, Česlovas Venclovas, Michael E. Colvin, Patricia A. Burke, Gerald L. DeNardo

Clin Cancer Res (2003) 9 (10): 3845s–3853s.

Published: 01 September 2003

View articletitled, Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy

Journal Articles

Dysregulation of PTEN and Protein Kinase B Is Associated with Glioma Histology and Patient Survival

Ralph P. Ermoian, Constance S. Furniss, Kathleen R. Lamborn, Daniel Basila, Mitchel S. Berger, Alexander R. Gottschalk, M. Kelly Nicholas, David Stokoe, Daphne A. Haas-Kogan

Clin Cancer Res (2002) 8 (5): 1100–1106.

Published: 01 May 2002

View articletitled, Dysregulation of PTEN and Protein Kinase B Is Associated with Glioma Histology and Patient Survival

Journal Articles

Aberrant p53, mdm2, and Proliferation Differ in Glioblastomas from Long-Term Compared with Typical Survivors¹

Eric C. Burton, Kathleen R. Lamborn, Peter Forsyth, James Scott, Jason O’Campo, Jane Uyehara-Lock, Michael Prados, Mitchel Berger, Sandra Passe, Joon Uhm, Brian P. O’Neill, Robert B. Jenkins, Ken D. Aldape

Clin Cancer Res (2002) 8 (1): 180–187.

Published: 01 January 2002

View articletitled, Aberrant p53, mdm2, and Proliferation Differ in Glioblastomas from Long-Term Compared with Typical Survivors1

Journal Articles

⁶⁷Copper-2-Iminothiolane-6-[p-(Bromoacetamido)benzyl]-TETA-Lym-1 for Radioimmunotherapy of Non-Hodgkin's Lymphoma

Robert T. O'Donnell, Gerald L. DeNardo, David L. Kukis, Kathleen R. Lamborn, Sui Shen, Aina Yuan, Desiree S. Goldstein, Gary R. Mirick, Sally J. DeNardo

Clin Cancer Res (1999) 5 (10): 3330s–3336s.

Published: 01 October 1999

View articletitled, 67Copper-2-Iminothiolane-6-[p-(Bromoacetamido)benzyl]-TETA-Lym-1 for Radioimmunotherapy of Non-Hodgkin's Lymphoma

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma

Expression of the Hypoxia Marker Carbonic Anhydrase 9 Is Associated with Anaplastic Phenotypes in Meningiomas

Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody

Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma

Preclinical Evaluation of Cathepsin-degradable Peptide Linkers for Radioimmunoconjugates

Effect of Molecular Size of Pegylated Peptide on the Pharmacokinetics and Tumor Targeting in Lymphoma-Bearing Mice

Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane- N , N ′, N ″, N ‴-Tetraacetic Acid (DOTA)-Peptide versus 2IT-DOTA Monoclonal Antibody Linkage for RIT

Characterization of Human IgG Antimouse Antibody in Patients with B-Cell Malignancies

Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy

Dysregulation of PTEN and Protein Kinase B Is Associated with Glioma Histology and Patient Survival

Aberrant p53, mdm2, and Proliferation Differ in Glioblastomas from Long-Term Compared with Typical Survivors¹

⁶⁷Copper-2-Iminothiolane-6-[p-(Bromoacetamido)benzyl]-TETA-Lym-1 for Radioimmunotherapy of Non-Hodgkin's Lymphoma

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only